We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Disc Medicine Inc (IRON) USD0.0001 A

Sell:$70.00 Buy:$120.59 Change: $6.65 (9.68%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $6.65 (9.68%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $6.65 (9.68%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in discovering, developing, and commercializing treatments for patients who suffer from serious hematologic diseases. It is building a portfolio of therapeutic candidates that focuses to address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin, which is for the treatment of erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP) and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD); MWTX-003 for the treatment of polycythemia vera (PV), and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, which is for the treatment of anemia associated with inflammatory diseases.

Contact details

321 Arsenal Street, Suite 101
United States
+1 (617) 6749274

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.82 billion
Shares in issue:
24.14 million
United States
US dollar

Key personnel

  • Donald Nicholson
    Executive Chairman of the Board
  • John Quisel
    President, Chief Executive Officer, Director
  • Jean Franchi
    Chief Financial Officer, Treasurer
  • Jonathan Yu
    Chief Operating Officer
  • Rahul Khara
    General Counsel
  • Brian Macdonald
    Chief Innovation Officer
  • William Savage
    Chief Medical Officer
  • Pamela Stephenson
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.